Half Year 2024 Circio Holding ASA Earnings Call TranscriptAug 29, 2024kr1.35 (+3.86%)Earnings- Q4 2022 Targovax ASA Earnings Call TranscriptFeb 16, 2023kr31.09 (+3.35%)Earnings
- Q3 2022 Targovax ASA Earnings Call TranscriptNov 03, 2022kr34.41 (-2.35%)Earnings
- Q2 2022 Targovax ASA Earnings Call TranscriptAug 18, 2022kr42.58 (-8.06%)Earnings
- Q1 2022 Targovax ASA Earnings Call TranscriptMay 12, 2022kr44.12 (-4.97%)Earnings
- Q4 2021 Targovax ASA Earnings Presentation TranscriptFeb 17, 2022
- Q3 2021 Targovax ASA Earnings Call TranscriptNov 04, 2021kr125.93 (-6.31%)Earnings
- Q2 2021 Targovax ASA Earnings Call TranscriptAug 18, 2021kr167.1 (-5.48%)Earnings
- Q1 2021 Targovax ASA Earnings Call TranscriptMay 06, 2021kr179.21 (-4.39%)Earnings
- Targovax ASA Corporate Analyst Meeting TranscriptFeb 18, 2021
- Targovax ASA - Special Call TranscriptDec 02, 2020
- Q3 2020 Targovax ASA Earnings Call TranscriptNov 05, 2020kr166.13 (+9.94%)Earnings
- Q2 2020 Targovax ASA Earnings Call TranscriptAug 20, 2020kr159.35 (-2.52%)Earnings
- Targovax ASA Corporate Analyst Meeting TranscriptJun 25, 2020
- Q1 2020 Targovax ASA Earnings Call TranscriptMay 07, 2020kr197.61 (-7.80%)Earnings
- Q4 2019 Targovax ASA Earnings Call TranscriptMar 11, 2020kr106.56 (-10.02%)Earnings
- Targovax ASA - Pre Recorded Special Call TranscriptJan 21, 2020
- Targovax ASA - Special Call TranscriptNov 15, 2019
- Q3 2019 Targovax ASA Earnings Call TranscriptNov 07, 2019kr125.69 (+2.77%)Earnings
- Q2 2019 Targovax ASA Earnings Call TranscriptAug 22, 2019kr134.89 (-4.30%)Earnings
- Q1 2019 Targovax ASA Earnings Call TranscriptMay 09, 2019kr153.78 (-3.79%)Earnings
Q2 2019 Targovax ASA Earnings Call Transcript
Ladies and gentlemen, welcome to Targovax's quarterly presentation. My name is Ãystein Soug. I'm the CEO. And together with me today, we have Magnus Jäderberg, who's the Chief Medical Officer; and Torbjørn Furuseth, who is the CFO of the company. There will be possibilities to ask questions from the room after the presentation. But during the presentation, everyone can file your questions on the web, and we will answer them as we finish.
Now in Targovax, we develop oncolytic viruses. And our lead product is called ONCOS-102. It's an oncolytic adenovirus that we use to make cultured mesoth, which means, in essence, to produce T-cells to kill cancers. We are one of the furthest-developed oncolytic viruses on the market today. We have compelling Phase I data, and currently, ONCOS-102 is in 4 different combination trials. We're combining both with chemotherapy and with checkpoint inhibitors.
Since 2016/2017, we have started and recruited patients into 4 trials that are currently maturing, to the extent that we are now seeing those trials
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
